Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth W Mahaffey

Showing results (121-130 of 635) with videos related to

Pageof 64
Sort By:
Diabetes, Obesity & Metabolism|August 17, 2021
Reasons for hospitalizations in patients with type 2 diabetes in the CANVAS programme: A secondary analysisKent Y Feng, JingWei Li, Juliana Ianus, et al.
American Heart Journal|July 1, 2008
Smoking status and antithrombin therapy in patients with non-ST-segment elevation acute coronary syndromeSteve Leung, Dianne Gallup, Kenneth W Mahaffey, et al.
Diabetes, Obesity & Metabolism|March 1, 2017
Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trialsBruce Neal, Vlado Perkovic, Kenneth W Mahaffey, et al.
The American Journal of Cardiology|April 19, 2017
Effect of Atrial Fibrillation on Mortality, Stroke Risk, and Quality-of-Life Scores in Patients With Heart Failure (from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF])Tharian S Cherian, Peter Shrader, Gregg C Fonarow, et al.
European Journal of Heart Failure|January 23, 2025
Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: A participant-level pooled analysis of the CANVAS and CREDENCE trialsSafia Chatur, Muthiah Vaduganathan, Robert A Fletcher, et al.
The New England Journal of Medicine|November 15, 2021
Milvexian for the Prevention of Venous ThromboembolismJeffrey I Weitz, John Strony, Walter Ageno, et al.
American Heart Journal|March 17, 2022
Independence of clinical events committees: A consensus statement from clinical research organizationsErnest Spitzer, Alexander C Fanaroff, C Michael Gibson, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|May 1, 2010
Enoxaparin 0.3 mg/kg IV supplement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTE ACS: a subgroup analysis from the SYNERGY trialMarc Cohen, Glenn N Levine, Karen S Pieper, et al.
Clinical Cardiology|March 12, 2014
Comparison of clinical trial outcome patterns in patients following acute coronary syndromes and in patients with chronic stable atherosclerosisKenneth W Mahaffey, Daniel M Wojdyla, Karen S Pieper, et al.
Diabetes, Obesity & Metabolism|January 19, 2023
Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trialAkihiko Koshino, Megumi Oshima, Clare Arnott, et al.
Pageof 64

Showing results (121-130 of 635) with videos related to

Sort By:
Pageof 64
Diabetes, Obesity & Metabolism|August 17, 2021
Reasons for hospitalizations in patients with type 2 diabetes in the CANVAS programme: A secondary analysisKent Y Feng, JingWei Li, Juliana Ianus, et al.
American Heart Journal|July 1, 2008
Smoking status and antithrombin therapy in patients with non-ST-segment elevation acute coronary syndromeSteve Leung, Dianne Gallup, Kenneth W Mahaffey, et al.
Diabetes, Obesity & Metabolism|March 1, 2017
Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trialsBruce Neal, Vlado Perkovic, Kenneth W Mahaffey, et al.
The American Journal of Cardiology|April 19, 2017
Effect of Atrial Fibrillation on Mortality, Stroke Risk, and Quality-of-Life Scores in Patients With Heart Failure (from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF])Tharian S Cherian, Peter Shrader, Gregg C Fonarow, et al.
European Journal of Heart Failure|January 23, 2025
Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: A participant-level pooled analysis of the CANVAS and CREDENCE trialsSafia Chatur, Muthiah Vaduganathan, Robert A Fletcher, et al.
The New England Journal of Medicine|November 15, 2021
Milvexian for the Prevention of Venous ThromboembolismJeffrey I Weitz, John Strony, Walter Ageno, et al.
American Heart Journal|March 17, 2022
Independence of clinical events committees: A consensus statement from clinical research organizationsErnest Spitzer, Alexander C Fanaroff, C Michael Gibson, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|May 1, 2010
Enoxaparin 0.3 mg/kg IV supplement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTE ACS: a subgroup analysis from the SYNERGY trialMarc Cohen, Glenn N Levine, Karen S Pieper, et al.
Clinical Cardiology|March 12, 2014
Comparison of clinical trial outcome patterns in patients following acute coronary syndromes and in patients with chronic stable atherosclerosisKenneth W Mahaffey, Daniel M Wojdyla, Karen S Pieper, et al.
Diabetes, Obesity & Metabolism|January 19, 2023
Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trialAkihiko Koshino, Megumi Oshima, Clare Arnott, et al.
Pageof 64